Katz, Deborah AMorris, Joan DChu, Michael PDavid, Kevin AThieblemont, CatherineMorley, Nicholas JKhan, Sharif SViardot, AndreasMartín García-Sancho, AlejandroRodríguez-García, GuillermoBastos-Oreiro, MarianaLee, Seung TaeKormany, WilliamChen, YuqiWong, Hansen LAnderson, Abraham AKatlinskaya, YuliyaAvilion, Ariel ADai, TianGonzález-Barca, Eva2023-05-032023-05-032022-05-03http://hdl.handle.net/10668/19676This open-label, multicenter, single-arm, phase 2 study assessed the safety and efficacy of blinatumomab consolidation therapy in adult patients with newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL; International Prognostic Index 3-5 and/or double-/triple-hit or double MYC/BCL-2 expressors) who achieved complete response (CR), partial response (PR), or stable disease (SD) following run-in with 6 cycles of R-chemotherapy (NCT03023878). Of the 47 patients enrolled, 28 received blinatumomab. Five patients (17.9%) experienced grade 4 treatment-emergent adverse events of interest (neutropenia, n = 4; infection, n = 1). Two deaths reported at the end of the study were unrelated to treatment with blinatumomab (disease progression, n = 1; infection, n = 1). 3/4 patients with PR and 4/4 patients with SD after R-chemotherapy achieved CR following blinatumomab. Consolidation with blinatumomab in patients with newly diagnosed, high-risk DLBCL who did not progress under R-chemotherapy was better tolerated than in previous studies where blinatumomab was used for treatment of patients with lymphoma.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Relapsed/refractoryblinatumomabhigh-risk DLBCLAdultAntibodies, BispecificHumansLymphoma, Large B-Cell, DiffuseProto-Oncogene Proteins c-bcl-2Remission Inductionresearch article35503708open access10.1080/10428194.2022.20649811029-2403https://doi.org/10.1080/10428194.2022.2064981